# A Phase II Study of GC101 in NSCLC

> **NCT07560111** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 28 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Autologous Tumor Infiltrating Lymphocytes

## Key facts

- **NCT ID:** NCT07560111
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560111, "A Phase II Study of GC101 in NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07560111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*